Barclays’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
Other funds holding KNSA
BBA
Barclays's KNSA Position: Q3 2026 in Review
Barclays increased its Kiniksa Pharmaceuticals (KNSA) stake by 202% in Q3 2026, buying an estimated $1.95M and bringing the position to 39,687 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2354.
Barclays first reported a position in KNSA in Q3 2018 and has held it in 33 quarters since. The position peaked at $12M in Q4 2020. 305 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.
- Barclays held 39,687 shares of Kiniksa Pharmaceuticals worth $2.96M as of Q3 2026.
- Barclays bought 26,525 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $1.95M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2354 holding.
- Barclays first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 33 quarters since.
- Barclays's Kiniksa Pharmaceuticals position peaked at $12M in Q4 2020.
- 305 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.